摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-methoxypiperidine trifluoroacetic acid salt | 741288-39-1

中文名称
——
中文别名
——
英文名称
4-methoxypiperidine trifluoroacetic acid salt
英文别名
4-methoxypiperidine trifluoroacetate salt;4-methoxypiperidine trifluoroacetate;4-methoxypiperidine;2,2,2-trifluoroacetic acid
4-methoxypiperidine trifluoroacetic acid salt化学式
CAS
741288-39-1
化学式
C2HF3O2*C6H13NO
mdl
——
分子量
229.199
InChiKey
MILUQWSBTZOVMZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.02
  • 重原子数:
    15
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.88
  • 拓扑面积:
    58.6
  • 氢给体数:
    2
  • 氢受体数:
    7

反应信息

  • 作为反应物:
    描述:
    4-methoxypiperidine trifluoroacetic acid salt4-二甲氨基吡啶三乙胺 、 sodium hydroxide 作用下, 以 1,4-二氧六环二氯甲烷甲苯 为溶剂, 反应 36.0h, 生成 (1R,3S)-1-benzyl 3-((1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-3a-(4-methoxypiperidin-1-carbonyl)-5a,5b,8,8,11a-pentamethyl-1-(1-methylcyclopropyl)icosahydro-1H-cyclopenta[a]chrysen-9-yl)-2,2-dimethylcyclobutan-1,3-dicarboxylate
    参考文献:
    名称:
    [EN] NOVEL BETULINIC ACID DERIVATIVES AS HIV INHIBITORS
    [FR] NOUVEAUX DÉRIVÉS D'ACIDE BÉTULINIQUE À TITRE D'INHIBITEURS DU VIH
    摘要:
    公开号:
    WO2013160810A3
  • 作为产物:
    描述:
    N-叔丁氧羰基-4-哌啶酮甲醇 、 sodium tetrahydroborate 、 sodium hydride 作用下, 以 四氢呋喃二氯甲烷 、 mineral oil 为溶剂, 反应 4.17h, 生成 4-methoxypiperidine trifluoroacetic acid salt
    参考文献:
    名称:
    [EN] NOVEL BETULINIC ACID DERIVATIVES AS HIV INHIBITORS
    [FR] NOUVEAUX DÉRIVÉS D'ACIDE BÉTULINIQUE À TITRE D'INHIBITEURS DU VIH
    摘要:
    公开号:
    WO2013160810A3
点击查看最新优质反应信息

文献信息

  • [EN] 1-(DIHYDRONAPHTHALENYL)PYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS<br/>[FR] 1-(DIHYDRONAPHTALÉNYL)PYRIDONES EN TANT QU'ANTAGONISTES DU RÉCEPTEUR 1 DE L'HORMONE DE CONCENTRATION DE LA MÉLANINE
    申请人:GLAXOSMITHKLINE LLC
    公开号:WO2013149362A1
    公开(公告)日:2013-10-10
    Provided are 1-(dihydronaphthalenyl)pyridones which are antagonists at the melanin-concentrating hormone receptor 1 (MCHR1), pharmaceutical compositions containing them, processes for their preparation, and their use in therapy for the treatment of obesity and diabetes.
    提供的是1-(二氢基)吡啶酮,它们是黑素浓集激素受体1(MCHR1)的拮抗剂,包含它们的药物组合物,它们的制备过程,以及它们在治疗肥胖和糖尿病方面的用途。
  • PYRAZOLE DERIVATIVES
    申请人:DAIICHI PHARMACEUTICAL CO., LTD.
    公开号:EP1762568A1
    公开(公告)日:2007-03-14
    A compound represented by formula (I): (wherein Ar1 represents a phenyl group which may have 1 to 3 substituents, or a non-substituted 5- or 6-membered aromatic heterocyclic group; Ar2 represents (i) a non-substituted phenyl group, (ii) a phenyl group which has been substituted by a lower alkyl group having 1 to 3 groups or atoms selected from among a carbamoyl group, an amino group, a hydroxyl group, a lower alkoxy group, and a halogen atom, or (iii) a 5- or 6-membered nitrogen-containing aromatic heterocyclic group which has been substituted by 1 to 3 groups or atoms selected from among a lower alkyl group, a lower alkynyl group, a lower alkanoyl group, a carbamoyl group, a cyano group, an amino group, a hydroxyl group, a lower alkoxy group, and a halogen atom; and X represents a group represented by formula (II): (wherein the ring structure represents a 4- to 7-membered heterocyclic group which may have, in addition to the nitrogen atom shown in formula (II), one heteroatom selected from among nitrogen, oxygen, and sulfur, and which may be substituted by 1 to 4 groups or atoms selected from among a lower alkyl group, a carbamoyl group, an amino group, a hydroxyl group, a lower alkoxy group, an oxo group, a lower alkanoyl group, a lower alkylsulfonyl group, and a halogen atom)), a salt thereof, a solvate of the compound or the salt, and a drug.
    由式(I)表示的化合物: (其中Ar1代表可能具有1到3个取代基的苯基,或者是非取代的5-或6-成员芳香杂环基团;Ar2代表(i)非取代的苯基团,(ii)已被1到3个来自羰胺基、基、羟基、低烷氧基和卤原子的群或原子取代的较低烷基基团取代的苯基团,或者(iii)已被1到3个来自低烷基基团、低炔基基团、低烷酰基团、羰胺基、基、基、羟基、低烷氧基和卤原子的群或原子取代的5-或6-成员含氮芳香杂环基团;X代表由式(II)表示的基团: (其中环结构表示可能具有除了式(II)中显示的氮原子之外,从氮、氧和中选择的一个杂原子的4-到7-成员杂环基团,并且可能被1到4个来自低烷基基团、羰胺基、基、羟基、低烷氧基、氧基、低烷酰基团、低烷基磺酰基团和卤原子的群或原子取代)),其盐,该化合物或其盐的溶剂化合物,以及药物。
  • Heterocyclic-substituted phenyl methanones
    申请人:Jolidon Synese
    公开号:US20060178381A1
    公开(公告)日:2006-08-10
    The present invention relates to compounds of formula I wherein R 1 , R 2 , and are defined in the specification and to pharmaceutically acceptable acid addition salts thereof.
    本发明涉及式I的化合物 其中 R 1 , R 2 ,并在规范中定义,并且其药学上可接受的酸盐。
  • Pyrazole derivative
    申请人:Kanaya Naoaki
    公开号:US20060128685A1
    公开(公告)日:2006-06-15
    The present invention is directed to a strong platelet aggregation-inhibiting agent which does not inhibit COX-1 or COX-2. The present invention provides compounds represented by formula (I) or formula (II), salts of the compounds, and solvates of the compounds or the salts. Also provided are medicaments containing any of the compounds, salts, or solvates and preventive and/or therapeutic agents for ischemic diseases, containing any of the compounds, salts, or the solvates.
    本发明旨在提供一种强的血小板聚集抑制剂,其不抑制COX-1或COX-2。本发明提供了由式(I)或式(II)表示的化合物,化合物的盐以及化合物或盐的溶剂。还提供了包含任何一种化合物、盐或溶剂的药物以及预防和/或治疗缺血性疾病的制剂,其中包含任何一种化合物、盐或溶剂。
  • Pyrazole Derivatives
    申请人:Kanaya Naoaki
    公开号:US20080064682A1
    公开(公告)日:2008-03-13
    A compound represented by formula (I): (wherein Ar 1 represents a phenyl group which may have 1 to 3 substituents, or a non-substituted 5- or 6-membered aromatic heterocyclic group; Ar 2 represents (i) a non-substituted phenyl group, (ii) a phenyl group which has been substituted by a lower alkyl group having 1 to 3 groups or atoms selected from among a carbamoyl group, an amino group, a hydroxyl group, a lower alkoxy group, and a halogen atom, or (iii) a 5- or 6-membered nitrogen-containing aromatic heterocyclic group which has been substituted by 1 to 3 groups or atoms selected from among a lower alkyl group, a lower alkynyl group, a lower alkanoyl group, a carbamoyl group, a cyano group, an amino group, a hydroxyl group, a lower alkoxy group, and a halogen atom; and X represents a group represented by formula (II): (wherein the ring structure represents a 4- to 7-membered heterocyclic group which may have, in addition to the nitrogen atom shown in formula (II), one heteroatom selected from among nitrogen, oxygen, a sulfur, and which may be substituted by 1 to 4 groups or atoms selected from among a lower alkyl group, a carbamoyl group, an amino group, a hydroxyl group, a lower alkoxy group, an oxo group a lower alkanoyl group, a lower alkylsulfonyl group, and a halogen atom)), a salt thereof, a solvate of the compound or the salt, and a drug.
    化合物的化学式为(I):其中Ar1代表一个苯基,它可能有1到3个取代基,或者是一个非取代的5-或6-成员的芳香杂环基;Ar2代表(i)一个非取代的苯基,(ii)一个已经被1到3个来自羰基基团、基基团、羟基基团、低级烷氧基团和卤原子的较低烷基取代的苯基,或者(iii)一个已经被1到3个来自较低烷基、较低炔基、较低烷酰基、羰基基团、基基团、基基团、羟基基团、低级烷氧基团和卤原子的取代的5-或6-成员的含氮芳香杂环基;X代表一个化学式(II)所代表的基团:(其中环结构代表一个4-到7-成员的杂环基,它可能有除了在化学式(II)中显示的氮原子之外的一个来自氮、氧、的杂原子,它可能被1到4个来自较低烷基、羰基基团、基基团、羟基基团、低级烷氧基团、氧基基团、较低烷酰基、较低烷基磺酰基和卤原子的取代基所取代),它的盐、该化合物或其盐的溶剂化物,以及药物。
查看更多